DB 017Alternative Names: DB 017; rMMP10
Latest Information Update: 20 Jan 2016
At a glance
- Originator Digna Biotech
- Class Matrix metalloproteinases; Recombinant proteins
- Mechanism of Action Fibrinolysis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 20 Jan 2016 Preclinical trials in Stroke in Spain (unspecified route)
- 20 Jan 2016 Pharmacodynamics data from preclinical trials in stroke released by Digna Biotech (Digna Biotech pipeline, January 2016)